Company Overview and News

 
P&C Insurers Q1 Earnings Roster for Apr 24: CB, TRV & More

30m zacks
The first-quarter earnings season is in its first leg with 87 members of the elite S&P 500 index having already reported financial numbers so far. Per the latest Earnings Preview, performances of these index participants indicate 25% increase in total earnings on 10.7% higher revenues. The beat ratio is impressive with 82.8% companies surpassing bottom-line expectations and 67.8% outperforming on the top-line front.
Upvote Downvote

 
Can Catastrophe Loss Mar Chubb's (CB) Q1 Earnings Prospects?

2018-04-20 zacks
Chubb Limited (CB - Free Report) is slated to report first-quarter 2018 results on Apr 24 after the market closes. Last quarter, the company delivered a positive earnings surprise of 37.23%. Let’s see, how things are shaping up for this announcement. Chubb’s first quarter underwriting results will be affected by the California mudslides (which occurred in early January). Chubb has projected catastrophe loss from the same at nearly $125 million after tax while the total catastrophe loss is estimated at $305 million after tax.
Upvote Downvote

 
Will Selective Insurance's Cat Loss Ail Earnings in Q1? (Revised)

2018-04-20 zacks
Selective Insurance Group, Inc. (SIGI - Free Report) has announced catastrophe loss estimates of about $26 million, emanating from winter storm that impacted the east coast of the United States in early January 2018 and the Nor'easters in March. This apart, the company also estimated non-catastrophe insured property loss of $28 million from early January deep freeze in the company's footprint states and a relatively large number of severe fire loss.
Upvote Downvote

 
UPDATE 1-New York governor presses banks, insurers to weigh risk of NRA ties

2018-04-20 reuters
NEW YORK, April 19 (Reuters) - New York Governor Andrew Cuomo on Thursday ramped up pressure on banks and insurers to revisit whether their ties to the National Rifle Association and other gun rights groups harm their reputations and the public interest.
Upvote Downvote

 
New York governor presses banks, insurers to weigh risk of NRA ties

2018-04-19 reuters
NEW YORK, April 19 (Reuters) - New York Governor Andrew Cuomo on Thursday ramped up pressure on banks and insurers to revisit whether their ties to the National Rifle Association and other gun rights groups harm their reputations and the public interest.
Upvote Downvote

 
Everest Re (RE) Issues Catastrophe Loss Estimates for Q1

2018-04-12 zacks
Everest Re Group, Ltd. (RE - Free Report) has recently provided catastrophe loss estimate of $100 million for the first quarter of 2018, mainly attributable to the California wildfires and other weather-related events. These losses are net of reinsurance recoverables and reinstatement premiums. Notably, the property and casualty (P&C) insurer had incurred catastrophe loss of $161.5 million in fourth-quarter 2017, stemming from both the Northern and Southern California wildfires.
Upvote Downvote

 
Will Selective Insurance's Cat Loss Ail Earnings in Q1?

2018-04-10 zacks
Selective Insurance Group, Inc. (SIGI - Free Report) has recently announced catastrophe loss estimates of about $26 billion, emanating from winter storm that impacted the east coast of the United States in early January 2018 and the Nor'easters in March. This apart, the company also estimated non-catastrophe insured property loss of $28 million from early January deep freeze in the company's footprint states and a relatively large number of severe fire loss.
Upvote Downvote

 
The Zacks Analyst Blog Highlights: Alphabet, Chevron, Raytheon, Chubb and T. Rowe

2018-04-09 zacks
Chicago, IL – April 9, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Alphabet (GOOGL - Free Report) , Chevron (CVX - Free Report) , Raytheon (RTN - Free Report) , Chubb (CB - Free Report) and T. Rowe Price (TROW - Free Report) .
Upvote Downvote

 
Top Research Reports for Alphabet, Chevron & Raytheon

2018-04-06 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Chevron (CVX) and Raytheon (RTN). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Upvote Downvote

 
Chubb CEO Worried About U.S. Nationalism, Instability in Letter - Bloomberg

2018-04-06 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
To Be More Than A Yield Play, Zurich Insurance Needs More Self-Improvement

2018-04-06 seekingalpha
Zurich Insurance's performance has been dragged down by high loss ratios and high expense ratios, both of which the company is targeting with multiyear improvement strategies.
Upvote Downvote

 
Travelers or Progressive: Which is Better Ahead of Earnings?

2018-04-06 zacks
Riding high on an improving economic backdrop, increasing interest rates and a benign catastrophe environment, the insurance industry seems well-placed to facilitate players in ramping up their growth profile. Recently, the Fed has raised the interest rate by 25 basis points under the new chairman Jerome Powell and the rate now stands at 1.75%. The Federal Reserve has hinted at two more hikes in 2018 followed by three in 2019 and two in 2020, thus pushing up the rate to 3.
Upvote Downvote

1
Top Analyst Upgrades and Downgrades: ADM, Boeing, Hess, LogMeIn, NetApp, Sunrun, United Continental, Valeant, XPO and More

2018-04-06 247wallst
Stocks were weak on Friday morning ahead of the unemployment and payrolls report, due to an expanded potential of $100 billion more in tariffs against China. The market has been swinging up and down, the bull market is now over nine years old, and the trend of buying pullbacks has become much more vulnerable to sellers and volatility trades. All this is making it harder for investors to decide how they want their assets positioned for the rest of 2018 and beyond.
Upvote Downvote

 
4 Solid Insurance Stock Picks: Can These Continue the Bull Run?

2018-04-06 investorplace
As the year 2018 set in, the insurance industry started to witness the wheel of fortune turning in its favor with the rising interest rates, improving economy, lower-than-expected catastrophe loss (as compared to 2017, which emerged as the costliest year in terms of cat loss) as well as a noteworthy tax reform effective Jan 1, 2018.
Upvote Downvote

 
4 Solid Insurance Picks: Can These Continue the Bull Run?

2018-04-05 zacks
As the year 2018 set in, the insurance industry started to witness the wheel of fortune turning in its favor with the rising interest rates, improving economy, lower-than-expected catastrophe loss (as compared to 2017, which emerged as the costliest year in terms of cat loss) as well as a noteworthy tax reform effective Jan 1, 2018. Hence, the industry is anticipated to deliver better-than-expected results and continue the momentum in the near term as well.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: H1467J104